Category Archives: Top Market News

Cantor Fitzgerald Thinks Aptinyx Inc’s Stock is Going to Recover

Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Aptinyx Inc (APTX – Research Report) today and set a price target of $40. The company’s shares opened today at $6, close to its 52-week low of $5.51. Duncan said:

Pivotal Research Reaffirms Their Hold Rating on Snap Inc (SNAP)

In a report released today, Brian Wieser from Pivotal Research reiterated a Hold rating on Snap Inc (SNAP – Research Report), with a price target of $6. The company’s shares closed yesterday at $6.54, close to its 52-week low of

Analysts Conflicted on These Healthcare Names: Eyenovia Inc (NASDAQ: EYEN), Galectin Therapeutics (NASDAQ: GALT) and Advaxis (NASDAQ: ADXS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eyenovia Inc (EYEN – Research Report), Galectin Therapeutics (GALT – Research Report) and Advaxis (ADXS – Research Report). Eyenovia Inc (EYEN) H.C. Wainwright analyst Ram

VBI Vaccines (VBIV) Receives a New Rating from Oppenheimer

VBI Vaccines (VBIV – Research Report) received a Buy rating and a $9 price target from Oppenheimer analyst Leland Gershell today. The company’s shares closed yesterday at $1.77. Gershell noted: “We are initiating coverage on VBIV with an Outperform rating

Wells Fargo Sticks to Their Buy Rating for WEX (WEX)

Wells Fargo analyst Timothy Willi maintained a Buy rating on WEX (WEX – Research Report) today. The company’s shares closed yesterday at $154.82. According to TipRanks.com, Willi is a 4-star analyst with an average return of 7.6% and a 57.1%

New Buy Rating for AstraZeneca (AZN), the Healthcare Giant

BMO Capital analyst Alex Arfaei maintained a Buy rating on AstraZeneca (AZN – Research Report) yesterday and set a price target of $48. The company’s shares closed yesterday at $36.11. According to TipRanks.com, Arfaei is a 5-star analyst with an